Clinical Trials Logo

Pregnancy, High Risk clinical trials

View clinical trials related to Pregnancy, High Risk.

Filter by:

NCT ID: NCT03718104 Recruiting - Clinical trials for Alcohol Use Disorder

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

Start date: December 1, 2018
Phase:
Study type: Observational

This is a multi-center prospective comparative cohort study examining the safety, efficacy, pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use disorder. Pregnancy, delivery, and maternal and infant outcomes to 12 months post-delivery will be examined and compared with a cohort treated with buprenorphine/naloxone.

NCT ID: NCT03061864 Recruiting - Anxiety Clinical Trials

The Periviable Birth Plan

Start date: August 2016
Phase: N/A
Study type: Interventional

Pregnant women who are at risk of delivering their infants in the periviable period can suffer a large amount of stress and anxiety. Moreover, many women feel a loss of control over their own pregnancy. There is some evidence that more counseling and planning can help reduce maternal stress and anxiety. Patients at risk of delivering in the periviable period will be randomized to either receive standard counselling or to complete the periviable birth plan.

NCT ID: NCT01891240 Recruiting - Pregnancy Clinical Trials

IMproved PRegnancy Outcome by Early Detection

IMPROvED
Start date: November 2013
Phase: N/A
Study type: Observational

The overall objective of the IMPROvED project is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for preeclampsia. This will involve a multicentre, phase IIa clinical predictive study to assess and refine novel and innovative prototype tests based on emerging metabolomic and proteomic technologies developed by SMEs (small to medium size enterprise) within the consortium. The study will i) recruit 5000 first-time pregnant women; ii) establish a high calibre biobank, augmented by accurate clinical metadata; iii) determine whether prototype predictive assays and algorithms translate to the clinical environment; iv) assess potential synergy of a combined metabolomic and proteomic approach and v) progress regulatory approval and development of the selected test into the clinical arena.